Check out our latest news
MSWA plays key role in providing improved access to Tysabri®
As of 1 February 2024, the federal government approved subcutaneous natalizumab (Tysabri®) for individuals with relapsing remitting MS (RRMS) under the Pharmaceutical Benefits Scheme (PBS).
Decision-making capacity
People make countless decisions every day. They can be deeply personal and are often informed by your values, your experiences and people closest to you.
Egg-cellent Choices for a Healthier Easter
With Easter just around the corner, it's time to embrace the festivities while keeping our wellbeing in mind. Here are some evidence-based tips from a Dietitian for a healthful and joyful Easter.